Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
Simon B DrysdaleKatrina CathieFlorence FlameinMarkus KnufAndrea M CollinsHelen C HillFriedrich KaiserRobert CohenDidier PinquierChristian T FelterNatalya C VassilouthisJing JinMathieu BangertKarine MariRapi NteeneSophie WagueMichelle RobertsPierre TissèresSimon RoyalSaul N Faustnull nullPublished in: The New England journal of medicine (2024)
Nirsevimab protected infants against hospitalization for RSV-associated lower respiratory tract infection and against very severe RSV-associated lower respiratory tract infection in conditions that approximated real-world settings. (Funded by Sanofi and AstraZeneca; HARMONIE ClinicalTrials.gov number, NCT05437510).
Keyphrases